CA Patent

CA3196650A1 — Levodopa dosing regimen

Assigned to Amneal Pharmaceuticals LLC · Expires 2022-06-30 · 4y expired

What this patent protects

The invention provides oral dosing regimens of controlled release levodopa compositions for use in treating patients with Parkinson's disease.

USPTO Abstract

The invention provides oral dosing regimens of controlled release levodopa compositions for use in treating patients with Parkinson's disease.

Drugs covered by this patent

Patent Metadata

Patent number
CA3196650A1
Jurisdiction
CA
Classification
—
Expires
2022-06-30
Drug substance claim
No
Drug product claim
No
Assignee
Amneal Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.